

Case report

Open Access

QT interval prolongation after sertraline overdose: a case report

Rudolf A de Boer*^{1,2}, Tonnis H van Dijk¹, Nicole D Holman¹ and Joost P van Melle^{2,1}

Address: ¹Department of Internal Medicine, Intensive Care Unit, Martini Hospital, Groningen, The Netherlands and ²Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

Email: Rudolf A de Boer* - rudolfdeboer@wanadoo.nl; Tonnis H van Dijk - th.van.dijk@mzh.nl; Nicole D Holman - n.holman@mzh.nl; Joost P van Melle - j.p.van.melle@thorax.umcg.nl

* Corresponding author

Published: 19 July 2005

Received: 26 April 2005

BMC Emergency Medicine 2005, 5:5 doi:10.1186/1471-227X-5-5

Accepted: 19 July 2005

This article is available from: <http://www.biomedcentral.com/1471-227X/5/5>

© 2005 de Boer et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) are the most common antidepressants used in first-world countries and are generally well tolerated. Specifically, less cardiovascular toxicity has been reported in comparison with tricyclic antidepressants. Here we report QT interval prolongation after an overdose of the SSRI sertraline.

Case presentation: A previously healthy female patient presented with an attempted suicide with overdoses sertraline (2250 mg), diazepam (200 mg), and temazepam (400 mg). Routine laboratory studies were normal and her ECG upon admission showed a normal QT interval. The next day, her ECG showed prolongation of the QT_c interval up to 525 ms. After discontinuation of sertraline the QT interval normalized. Echocardiography and exercise electrocardiography were normal. After hospitalization, the patient resumed sertraline in the normally recommended dose and QT interval remained within normal ranges.

Conclusion: It seems that the SSRI sertraline in overdose may cause QT interval prolongation.


Background

Since their introduction in 1987, the use of Selective Serotonin Reuptake Inhibitors (SSRIs) has increased dramatically [1]. They clearly have a more favorable safety profile compared to tricyclic antidepressants [2], although prolongation of the QT interval has been reported as a side effect [3]. This is an important side effect since prolongation of the QT interval is strongly associated with life-threatening arrhythmias, most notably torsades de pointes. Although sertraline belongs to the same class of antidepressants, controversy persists whether this holds true for the SSRI sertraline [4]. Here we here present a patient with prolonged QT interval after sertraline overdose.

Case presentation

A 40-year old female patient was referred to our emergency department because of an intended overdose with 200 mg diazepam, 400 mg temazepam, and 2250 mg sertraline.

Her main complaints were fatigue and drowsiness. Blood pressure, pulse rate, and auscultation of the heart and lungs were normal. The patient was treated with sodium-sulfate and charcoal and was admitted to the intensive care unit for continuous control of vital signs. Routine laboratory studies (hematology, chemistry) were normal. Plasma levels of diazepam and temazepam were elevated, 1155 ugr/l (normal: 125 – 750 ugr/l) and 1710 ugr/l

**Figure 1**

ECGs of the patient. ECG of the patient upon admission (upper panel) shows a normal sinus rhythm with a QT interval in lead V2 of 370 ms (QT_c 420 ms). There were negative T-waves in leads V1–V3. A second ECG was obtained one day after admission (lower panel) shows a markedly prolonged QT interval of 520 ms in V2 (QT_c 525 ms).

(normal: 300–900 ug/l, respectively). Plasma levels of sertraline and desmethylsertraline were 174 ug/l (normal 20–55 ug/l [5]) and 276 ng/l, respectively.

Her ECG upon admission (upper panel of the figure) shows a sinus rhythm (77 b.p.m.) without conduction disturbances. QT interval in lead V2 was 370 ms. We used the Bazett method (QT time divided by the square root of the RR interval) to calculate the corrected QT (QT_c). QT_c at admission was 420 ms and negative T-waves were found in leads V1–V3. A second ECG, taken one day after admission (lower panel of the figure), showed a markedly prolonged QT interval with deepened negative T waves in leads V1–V3. QT interval was 520 ms in V2, at a heart rate (HR) of 63 b.p.m (QT_c 525 ms). An old ECG (august 2002) showed a sinus rhythm with a HR of 63 b.p.m and a QT interval in lead V2 of 370 ms (QT_c 373 ms; ECG not shown).

After 4 days the patient was discharged to a psychiatric hospital because the risk for another suicide attempt was deemed high by the psychiatric consultant. After discharge, the patient underwent further out-patient cardiac evaluation. Echocardiography revealed no structural heart disease. On exercise electrocardiography, patient reached 88% of her maximum HR – no abnormal ST-segment changes were observed. Hereafter, the use of sertraline was resumed in a dose of 50 mg twice daily under guidance of her psychiatrist. Control ECG revealed a normal QT interval (not shown).

Discussion

We here present a patient with prolonged QT interval associated with sertraline overdose. An acquired cause of QT prolongation was suspected since QT intervals had been normal on admission, about 3 hours after ingestion of 2250 mg of sertraline (11 times the maximum recommended dose of 200 mg/day), and were markedly prolonged after one day in hospital. The QT interval normalized after sertraline withdrawal. Therefore, a temporal relation existed between the overdose of sertraline and the development of QT prolongation. However, other causes for QT prolongation, both acquired and inherited, must be considered. For example, combinations of psychoactive drugs have been shown to cause prolongation of the QT interval [6], and our patient ingested temazepam as well as nitrazepam in overdose.

Whereas previous clinical studies [7-10] did not reveal any QT prolongation as a side-effect of sertraline, this case report suggests it may have this potential. We are aware of 1 additional report by Amin et al [11] who described 'a clinically significant' increase in QT interval after treatment with 200 mg of sertraline, however the magnitude of QT prolongation was not specified.

Naturally, implications of this finding are limited because it is only a single case. Two other limitations deserve comment. First, we did not perform a rechallenge with high dosage of sertraline, since this would be unethical. Second, only one blood sample was taken to assess plasma concentration of sertraline – the sertraline plasma level was found clearly increased according to other reports [5,12]. It was therefore not possible to investigate the relation between the course of QT interval prolongation and their paralleled serum levels of sertraline

Conclusion

Our observation suggests that the SSRI sertraline may have the potential to prolong QT interval in rare cases. This case underscores the need for continuous post marketing surveillance.

List of abbreviations

HR heart rate

LV left ventricular

QT_c Corrected QT interval

SSRI selective serotonin reuptake inhibitor

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

RADB, THVD, and NDH cared for the patient in the intensive care unit, conducted QT analyses, and arranged laboratory samples. RADB and JPVM noticed that QT interval prolongation had not been discussed previously in the case of sertraline overdose. RADB, THVD, NDH wrote the paper, whereas JPVM critically revised the discussion for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

Written consent was obtained from the patient for publication of the patient's details.

References

1. Meijer WE, Heerdink ER, Leufkens HG, Herings RMC, Egberts ACG, Nolen WA: **Incidence and determinants of long-term use of antidepressants.** *Eur J Clin Pharmacol* 2004, **60**:57-61.
2. Kelsey JE, Nemeroff CB: **Selective serotonin reuptake inhibitors: introduction and overview.** In *Kaplan and Sadock's Comprehensive Textbook of Psychiatry* 7th edition. Edited by: Sadock BJ, Sadock VA. Philadelphia: Lippincott Williams & Wilkins; 2000:2432-2435.
3. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM: **What clinicians should know about the QT interval.** *JAMA* 2003, **289**:2120-2127.
4. Gillespie JA, Clary CM: **Medications that prolong the QT interval.** *JAMA* 2003, **290**:1025. (letter)
5. [<http://www.mdbrowse.com/Druginf/S/sertraline.htm#Sertraline>].
6. Sala M, Vicentini A, Brambilla P, Montomoli C, Jorgia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM: **QT interval pro-**

longation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. *Ann Gen Psychiatry* 2005, **4**:1.

7. Isbister GK, Bowe SJ, Dawson A, Whyte IM: **Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.** *J Toxicol Clin Toxicol* 2004, **42**:277-285.
8. Fisch C, Knoebel SB: **Electrocardiographic findings in sertraline depression trials.** *Drug Invest* 1992, **4**:305-312.
9. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: **Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.** *Biol Psychiatry* 1995, **38**:592-602.
10. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McIvor M, Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group: **Sertraline treatment of major depression in patients with acute MI or unstable angina.** *JAMA* 2002, **288**:701-709.
11. Amin M, Lehmann H, Mirmiran J: **A double-blind, placebo-controlled dose-finding study with sertraline.** *Psychopharmacol Bull* 1989, **25**:164-167.
12. Preskorn SH: **A tale of two patients.** *J Pract Psych Behav Health* 1999:160-164 [<http://www.preskorn.com/columns/9905.html>].

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-227X/5/5/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

